Year All202420232022202120202019 Opthea To Present at September 2021 Investor Conferences September 2, 2021 Read More Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights August 30, 2021 Read More Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference August 10, 2021 Read More Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada August 9, 2021 Read More Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration July 6, 2021 Read More Opthea Appoints Company Secretary and Vice President of Finance June 14, 2021 Read More Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors June 1, 2021 Read More Opthea Company Secretary Resignation April 6, 2021 Read More Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD March 31, 2021 Read More Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD March 15, 2021 Read More
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada August 9, 2021 Read More
Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration July 6, 2021 Read More
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors June 1, 2021 Read More